# Pyxis Oncology

Pyxis Oncology is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Assets under management:** Undisclosed
- **Website:** www.pyxisoncology.com
- **LinkedIn:** https://www.linkedin.com/company/pyxis-oncology

## Regulatory record

- **Reports private funds:** No

## About

Charting a course to therapeutics for difficult-to-treat cancers.

## Sectors

- Oncology
- Biotechnology

## People

- Thomas Civik — Interim Chief Executive Officer and Director
- John Flavin — Chair

## Questions

### Who makes investment decisions at Pyxis Oncology?

Pyxis Oncology is a publicly traded biotechnology company, not a family office or investment firm. Interim CEO Thomas Civik leads day-to-day operations, with strategic direction from a board of directors that includes John Flavin (Chair), Darren Cline, and several others (per the firm's website). The firm does not have a dedicated investment committee in the allocator sense; capital allocation decisions are made by management and the board.

### What is the lead therapeutic candidate and its mechanism?

Pyxis Oncology's lead candidate is micvotabart pelidotin (MICVO, formerly PYX-201), an antibody-drug conjugate targeting the extradomain-B splice variant of fibronectin, a protein found in the tumor microenvironment. Unlike most ADCs that target cell-surface antigens, MICVO targets a noncellular structural component of the extracellular matrix. It is designed to deliver a cytotoxic payload, induce bystander killing, and trigger immunogenic cell death (per the firm's pipeline page).

### What is the current clinical status of MICVO?

MICVO is being evaluated in Phase 1 clinical trials for various solid tumors, with a focus on recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The firm is also testing it in combination with Merck's Keytruda. The FDA granted Fast Track Designation for MICVO in R/M HNSCC. Updated monotherapy data is expected mid-2026, and combination data in the second half of 2026 (per the firm's pipeline page).

### What other assets are in Pyxis Oncology's pipeline?

Beyond MICVO, Pyxis Oncology's pipeline includes immuno-oncology monoclonal antibodies that aim to block cancer's defense mechanisms and activate immune components. The firm describes its approach as a 'differentiated portfolio of clinical assets' covering both ADCs and immunotherapies, but specific additional drug candidates beyond MICVO are not named on the public website.

## Related profiles

- [Deltek](https://altss.com/profile/deltek)
- [Barclays](https://altss.com/profile/barclays)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/pyxis-oncology

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology